Review
Accepted on 26 Nov 2024
AKR1B10 and Digestive Tumours Development: A Review
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1462174
Type at least 3 characters
6,699 articles
Articles
Case Report
Accepted on 26 Nov 2024
Case Report: Microsatellite instability-high pancreas adenosquamous carcinoma with postoperative liver metastasis recurrence treated with multimodality therapy achieving complete pathological response
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1456343
Original Research
Accepted on 26 Nov 2024
Pan-Cancer Analysis Shows That BCAP31 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1507375
Original Research
Published on 26 Nov 2024
A novel molecular classification system based on the molecular feature score identifies patients sensitive to immune therapy and target therapy
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1466069
- 399 views
Original Research
Published on 26 Nov 2024
Decoding NY-ESO-1 TCR T cells: transcriptomic insights reveal dual mechanisms of tumor targeting in a melanoma murine xenograft model
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1507218
- 312 views
Original Research
Published on 26 Nov 2024
Research hotspots and trends in immunotherapy for cholangiocarcinoma: a bibliometric analysis (2014-2023)
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1436315
- 217 views
Case Report
Published on 26 Nov 2024
A surprising complete response to cadonilimab in a primary metastatic cervical cancer: a case report
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1494138
- 237 views
Original Research
Published on 26 Nov 2024
Exploring RPA1-ETAA1 axis via high-throughput data analysis: implications for PD-L1 nuclear translocation and tumor-immune dynamics in liver cancer
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1492531
- 232 views
Review
Published on 26 Nov 2024
Traditional Chinese medicine and its components effectively reduce resistance mediated by immune checkpoint inhibitors
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1429483
- 104 views
Correction
Published on 26 Nov 2024
Corrigendum: Case report: A golden tail of immunotherapy: significant tail effect in a chemotherapy-resistant advanced pulmonary sarcomatoid carcinoma patient treated by Sintilimab combined with Anlotinib
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1527232
- 104 views
Clinical Trial
Published on 26 Nov 2024
Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1482715
- 251 views
Original Research
Published on 26 Nov 2024
FOLFOX-HAIC combined with targeted immunotherapy for initially unresectable hepatocellular carcinoma: a real-world study
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1471017
- 215 views
Original Research
Published on 26 Nov 2024
PRKDC regulates cGAMP to enhance immune response in lung cancer treatment
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1497570
- 139 views
Case Report
Published on 26 Nov 2024
Case report: The outcomes of neoadjuvant immunotherapy combined with chemotherapy in pulmonary sarcomatoid carcinoma: case series and literature review
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1467755
- 213 views
Mini Review
Published on 26 Nov 2024
Reprogramming the tumor microenvironment – macrophages emerge as key players in breast cancer immunotherapy
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1457491
- 525 views
Review
Published on 26 Nov 2024
Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentials
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1501613
- 240 views